What the Expanding Reach of Weight-Loss Drugs Means For Health Care 10/11/23

<p>Shares of medical device makers like Davita and Baxter International plunged after Novo Nordisk said its GLP-1 drug Ozempic had some positive results in trials against kidney failure. So what could the impact be of a potential do-it-all drug? We surround the trade with Dr. Kavita Patel and Mizuho’s Jared Holz.</p><p> </p><p><a href="https://www.cnbc.com/fast-money-disclaimer/"><strong>Fast Money Disclaimer</strong></a></p>